Unique Mechanisms of Action
• Biparatopic - targets two distinct HER2 epitopes and results in
• HER2 binding across a range of expression levels (low to high);
• HER2-receptor clustering, internalization, and downregulation;
• Inhibition of growth factor-dependent and -independent tumor cell proliferation;
• Potent antibody-dependent cellular cytotoxicity and phagocytosis, and complement-dependent cytotoxicity
Clinical Trial Highlights
• Clinical benefit1 observed across multiple HER2-expressing tumor types
• Zanidatamab + chemo shows durable activity in heavily pretreated patients
• FDA Breakthrough Therapy designation for pivotal trial in 2nd line biliary tract cancer
• 1L HER2+ GEA zanidatamab + chemo compares favorably to SOC; supports pivotal trial
• Initiated 2nd pivotal study of zanidatamab + tislelizumab + chemo in 1L+ line HER2+ GEA
• 3L+ HER2+ breast cancer zanidatamab + chemo compares favorably to SOC
